Terkko Navigator / British Journal of Haematology

Is COVID‐19 less severe in CML patients than in those with other haematological cancers?

Iron overload in inherited anaemias: why one size can't fit all

T cells to the rescue?

Comparative study of therapy‐related and de novo adult b‐cell acute lymphoblastic leukaemia

Identification of a novel GOLGA4–JAK2 fusion gene in B‐cell acute lymphoblastic leukaemia

Primary HBB gene mutation severity and long‐term outcomes in a global cohort of β‐thalassaemia

Laboratory diagnosis of iron deficiency: look out for the‘PITTs’

‘We cannot paint them all with the same brush’: the need for a better definition of patients with myelodysplastic syndromes for clinical trial design

Guideline for the laboratory diagnosis of iron deficiency in adults (excluding pregnancy) and children

Genetic characterisation of childhood B‐other‐acute lymphoblastic leukaemia in UK patients by fluorescence in situ hybridisation and Multiplex Ligation‐dependent Probe Amplification

Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies

Patient‐reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study

Clinical trial participation improves survival outcomes by increasing availability of new therapeutic agents in multiple myeloma

Interest of a third dose of BNT162b2 anti‐SARS‐CoV‐2 messenger RNA vaccine after allotransplant

Erythrophagocytosis in a patient with myelodysplastic syndrome with excess blasts‐1 with isolated del(6q)

Tracking the evolution of untreated high‐intermediate/high‐risk diffuse large B‐cell lymphoma by circulating tumour DNA

Serological response following BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccination in haematopoietic stem cell transplantation patients

Population‐based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large‐cell lymphoma using Public Health England data

Frequent health care utilisation and avascular necrosis are associated with cannabis use in adults with sickle cell disease

Integrating germline variant assessment into routine clinical practice for myelodysplastic syndrome and acute myeloid leukaemia: current strategies and challenges

Assessment of exposure to direct oral anticoagulants in elderly hospitalised patients

Paediatric ambiguous lineage leukaemia with monocytic differentiation at diagnosis: case series and review of literature

3q21 deletion affects GATA2 and is associated with myelodysplastic syndrome

Azacitidine for patients with Vacuoles, E1 Enzyme, X‐linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry

Unfolding the potential of anti‐programmed cell death protein 1 blockade in Hodgkin lymphoma – combination and personalisation?

T‐cell immune response after mRNA SARS‐CoV‐2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies

First report of novel heterozygous WRAP53 p.Ala522Glyfs*8 mutation associated dyskeratosis congenita

Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B‐cell lymphoma, leg type

Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMA

COVID‐19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report

Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV‐19 COVID‐19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors

Revised International Prognostic Index and genetic alterations are associated with early failure to R‐CHOP in patients with diffuse large B‐cell lymphoma

Intestinal pathophysiological abnormalities in steady state and after vaso‐occlusive crisis in murine sickle cell disease

Clinical significance of the immunoglobulin G heavy‐chain repertoire in peripheral blood mononuclear cells of adult T‐cell leukaemia–lymphoma patients receiving mogamulizumab

The wider perspective: twenty years of clinical trials in myelodysplastic syndromes

CD4+ T cells from patients with glucocorticoid‐refractory immune thrombocytopenia have altered cytokine expression

Conflicting impacts of tocilizumab and colchicine in COVID‐19‐associated coagulop

Real‐world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45‐year period

Impact of major bleeding and thrombosis on 180‐day survival in patients with severe COVID‐19 supported with veno‐venous extracorporeal membrane oxygenation in the United Kingdom: a multicentre observational study

Combination of PD‐1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second‐line therapy for relapsed/refractory classical Hodgkin lymphoma

Commentary: surviving sexism in bleeding disorders affecting women

Idiopathic multicentric Castleman disease of TAFRO subtype

TPO versus TPO: the good, the bad, and the to be determined

The immune landscape in BCR‐ABL negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy

Double‐hit multiple myeloma with atypical “faggot” cells

Epstein–Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features

Guidelines for the monitoring and management of iron overload in patients with haemoglobinopathies and rare anaemias

Novel therapies for immune thrombocytopenia

Intensified antiplatelet therapy in patients after percutaneous coronary intervention with high on‐treatment platelet reactivity: the OPTImal Management of Antithrombotic Agents (OPTIMA)‐2 Trial

Baseline creatinine predicts acute kidney injury during intensive therapy in transplant‐eligible patients with acute myeloid leukaemia